Literature DB >> 22801850

Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity.

Bjoern C Harder, Stefan von Baltz, Frank C Schlichtenbrede, Jost B Jonas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22801850     DOI： 10.1001/archophthalmol.2012.1

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN： 0003-9950


× No keyword cloud information.
  7 in total

Review 1.  Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review.

Authors:  Georgios N Tsiropoulos; Aikaterini K Seliniotaki; Anna-Bettina Haidich; Nikolaos Ziakas; Asimina Mataftsi
Journal:  Int Ophthalmol       Date:  2022-10-10       Impact factor: 2.029

2.  Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes.

Authors:  Y-H Chen; S-N Chen; R-I Lien; C-P Shih; A-N Chao; K-J Chen; Y-S Hwang; N-K Wang; Y-P Chen; K-H Lee; C-C Chuang; T-L Chen; C-C Lai; W-C Wu
Journal:  Eye (Lond)       Date:  2014-08-08       Impact factor: 3.775

3.  Development of refractive error in individual children with regressed retinopathy of prematurity.

Authors:  Jingyun Wang; Xiaowei Ren; Li Shen; Susan E Yanni; Joel N Leffler; Eileen E Birch
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-09-05       Impact factor: 4.799

Review 4.  A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.

Authors:  Laura Pertl; Gernot Steinwender; Christoph Mayer; Silke Hausberger; Eva-Maria Pöschl; Werner Wackernagel; Andreas Wedrich; Yosuf El-Shabrawi; Anton Haas
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

5.  Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity.

Authors:  Chun-Ju Lin; Yi-Yu Tsai
Journal:  Clin Ophthalmol       Date:  2016-07-21

Review 6.  Review of effects of anti-VEGF treatment on refractive error.

Authors:  Helen A Mintz-Hittner; Megan M Geloneck
Journal:  Eye Brain       Date:  2016-06-15

7.  Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review.

Authors:  Qing-Qing Tan; Stephen P Christiansen; Jingyun Wang
Journal:  PLoS One       Date:  2019-12-02       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.